ALL

Total75

All Title Content

• 
  BLOG 2026.08.10

  [AP NEWS] ABio Materials Expands International Operations Supporting Celexo Aesthetics Portfolio

  South Korean biotechnology company develops international distribution, education and market-development activities for its biomaterials portfolio Seoul, South Korea, August 7, 2026 -- ABio Materials Co., Ltd., a South Korean biotechnology company specializing in exosomes and biomaterials, announced the continued international expansion of its Celexo professional aesthetics portfolio. The company has developed an integrated technology platform encompassing research, extraction, stabilization, formulation and manufacturing. Its technologies include ExoTraction, an exosome extraction platform, and Cellularsome, a particle-stabilization technology used in the development of selected formulations. ABio Materials is developing Celexo as a professional aesthetics platform supported by its research into exosomes, PDRN, collagen and other biomaterials. The company’s portfolio includes Celexo Exo-Cica, a professional-use formulation containing Centella-derived exosome ingredients; CellExosome Black Label Skin, formulated with human adipose-derived extracellular vesicle ingredients; and CellExosome Black Label Hair, developed for professional scalp and hair care. Product classification, availability and permitted applications vary by country and jurisdiction. Products are introduced in individual markets in accordance with applicable local requirements. International Market Development ABio Materials has been developing its international presence through distributor relationships, professional education programs and participation in medical aesthetics events. The company has presented its technologies and product portfolio at the IMCAS World Congress in Paris, IMCAS Americas in São Paulo and International Beauty Expo Malaysia. These events provided opportunities to meet physicians, aesthetics professionals and prospective distribution partners from several international markets. ABio Materials is also pursuing applicable product registrations and distribution arrangements in selected markets across Europe, Southeast Asia and the Middle East. In North America, ABio Materials USA Inc. serves as the company’s local business base and supports market development, professional education and permitted distribution activities. The company is also developing business relationships across Europe, the Middle East, Asia and the Americas. The international expansion forms part of ABio Materials’ strategy to develop a diversified portfolio of professional aesthetics products based on its biomaterial research and formulation platforms. “The professional aesthetics sector is increasingly examining the technologies, formulations and scientific processes associated with biomaterial-based products,” an ABio Materials representative said. “Our ive is to expand Celexo’s international presence while continuing to develop the portfolio through our biotechnology research and manufacturing capabilities.” ABio Materials plans to continue developing its international distribution and professional network while conducting research and product-development activities involving exosomes, PDRN, collagen and other biomaterials. About ABio Materials Co., Ltd. ABio Materials Co., Ltd. is a South Korean biotechnology company involved in the research and development of exosomes, PDRN and other biomaterials for the professional aesthetics and cosmetics industries. The company develops professional skin and hair care formulations under the Celexo and CellExosome brands. ABio Materials USA Inc. supports the company’s business activities in North America. Product availability, regulatory status and permitted uses vary by jurisdiction. References to products or ingredients in this announcement do not constitute medical advice or claims that any product diagnoses, treats, cures or prevents a disease or medical condition. Company video:https://www.youtube.com/watch?v=a4EVyNigK48 Telephone: +82 2-6959-3734 Celexo:https://celexo.co.kr Contact Info: Name: Sukhyung Choi Email:Send Email Organization: ABio Materials Co., Ltd. Website:https://a-bio.co.kr   https://apnews.com/press-release/marketersmedia/press-release-1c45e0b7ca4d3f19f33b51df6db991c5

• 
  MEDIA 2026.08.10

  ABio Materials Expands International Operations Supporting Celexo Aesthetics Portfolio

      South Korean biotechnology company develops international distribution, education and market-development activities for its biomaterials portfolio Seoul, South Korea, August 7, 2026 -- ABio Materials Co., Ltd., a South Korean biotechnology company specializing in exosomes and biomaterials, announced the continued international expansion of its Celexo professional aesthetics portfolio. The company has developed an integrated technology platform encompassing research, extraction, stabilization, formulation and manufacturing. Its technologies include ExoTraction, an exosome extraction platform, and Cellularsome, a particle-stabilization technology used in the development of selected formulations. ABio Materials is developing Celexo as a professional aesthetics platform supported by its research into exosomes, PDRN, collagen and other biomaterials.   The company’s portfolio includes Celexo Exo-Cica, a professional-use formulation containing Centella-derived exosome ingredients; CellExosome Black Label Skin, formulated with human adipose-derived extracellular vesicle ingredients; and CellExosome Black Label Hair, developed for professional scalp and hair care. Product classification, availability and permitted applications vary by country and jurisdiction. Products are introduced in individual markets in accordance with applicable local requirements. International Market Development ABio Materials has been developing its international presence through distributor relationships, professional education programs and participation in medical aesthetics events. The company has presented its technologies and product portfolio at the IMCAS World Congress in Paris, IMCAS Americas in São Paulo and International Beauty Expo Malaysia. These events provided opportunities to meet physicians, aesthetics professionals and prospective distribution partners from several international markets. ABio Materials is also pursuing applicable product registrations and distribution arrangements in selected markets across Europe, Southeast Asia and the Middle East.   In North America, ABio Materials USA Inc. serves as the company’s local business base and supports market development, professional education and permitted distribution activities. The company is also developing business relationships across Europe, the Middle East, Asia and the Americas. The international expansion forms part of ABio Materials’ strategy to develop a diversified portfolio of professional aesthetics products based on its biomaterial research and formulation platforms. “The professional aesthetics sector is increasingly examining the technologies, formulations and scientific processes associated with biomaterial-based products,” an ABio Materials representative said. “Our ive is to expand Celexo’s international presence while continuing to develop the portfolio through our biotechnology research and manufacturing capabilities.” ABio Materials plans to continue developing its international distribution and professional network while conducting research and product-development activities involving exosomes, PDRN, collagen and other biomaterials. About ABio Materials Co., Ltd.   ABio Materials Co., Ltd. is a South Korean biotechnology company involved in the research and development of exosomes, PDRN and other biomaterials for the professional aesthetics and cosmetics industries. The company develops professional skin and hair care formulations under the Celexo and CellExosome brands. ABio Materials USA Inc. supports the company’s business activities in North America. Product availability, regulatory status and permitted uses vary by jurisdiction. References to products or ingredients in this announcement do not constitute medical advice or claims that any product diagnoses, treats, cures or prevents a disease or medical condition. Company video:https://www.youtube.com/watch?v=a4EVyNigK48 Telephone: +82 2-6959-3734 Celexo:https://celexo.co.kr Contact Info: Name: Sukhyung Choi Email:Send Email Organization: ABio Materials Co., Ltd. Website:https://a-bio.co.kr

• BLOG 2026.08.06

  Exosome-like Nanovesicles from Hordeum vulgare L. Fermented with Lactiplantibacillus plantarum BMSE-HMP251 Ameliorate LPS-Induced Inflammation in HT-29 and RAW 264.7 Cells

  Human breast milk harbors commensal lactic acid bacteria with probiotic potential, and microbial fermentation may enhance the bioactivity of plant-derived exosome-likenanovesi cles (EVs); this study evaluated whether L. plantarum BMSE-HMP251 isolated from breast milk could safely ferment Hordeum vulgare L. and improve the anti-inflammatory activity of derived EVs. BMSE-HMP251 was identified by 16S rRNA sequencing and characterized by biochemical, safety, and genomic analyses. EVs derived from Hordeum vulgare L. extract and BMSE-HMP251-fermented broth were evaluated for physicochemical properties, an tioxidant activity, cytotoxicity, and anti-inflammatory activity in LPS-stimulated HT-29 and RAW 264.7 cells. EVs derived from Hordeum vulgare L. fermentation exhibited a distinct size distribution and significantly enhanced bioactivity, including higher DPPH radical scavenging activity and greater suppression of nitric oxide production and proinflamma tory cytokine (TNF-α and IL-1β) mRNA expression, compared with EVs from unfermented extracts. These effects were observed following fermentation with the human breast milk derived strain L. plantarum BMSE-HMP251, which showed species-consistent phenotypic and genomic characteristics and no safety concerns. Overall, fermentation markedly en hances the anti-inflammatory potential of plant-derived EVs, supporting fermentation as a safe and effective strategy to improve their functional value. Keywords: fermentation; Lactiplantibacillus plantarum BMSE-HMP251; exosome-like nanovesicles; Hordeum vulgare L. anti-inflammatory activity

• BLOG 2026.08.06

  Exo-Cica/HA Complex Promotes Skin Rejuvenation and Barrier Repair via Extracellular Matrix Reconstruction and Anti-Inflammatory Regulation

  Background: Effective skin rejuvenation requires coordinated regulation of inflammation, restoration of epidermal barrier function, and reconstruction of the extracellular matrix (ECM) and basement membrane. Hyaluronic acid (HA) is widely used as a wound covering material that provides a hydrated microenvironment; however, its ability to actively regulate inflammation and structural remodeling is limited. Recently, plant derived exosome-like vesicles have emerged as potential bioactive regulators of skin rejuvenation. Objective: This study investigated whether a combined Exo-Cica/HA complex (Celexo), developed as a wound-covering material, enhances skin rejuvenation through anti inflammatory regulation, structural improvement of ECM, and restoration of epidermal barrier and basement membrane integrity. Methods: The biological effects of Exo-Cica/HA were evaluated using in vitro cellular models including keratinocytes, fibroblasts, macrophages, and melanocytes. Anti inflammatory activity, barrier-related gene expression, and basement membrane associated markers were analyzed using quantitative real-time polymerase chain reaction. Wound-healing potential was assessed using scratch assays. Ex-vivo human skin tissue models were employed to evaluate ECM remodeling, basement membrane restoration, barrier recovery, and re-epithelialization following ultraviolet B (UVB) irradiation or barrier disruption. Histological and immunofluorescence analyses were performed to examine structural tissue changes. Results: Exo-Cica/HA exhibited no cytotoxicity and significantly suppressed pro inflammatory cytokine expression. The treatment enhanced the expression of barrier related markers such as filaggrin and hyaluronan synthase-2 and upregulated basement membrane components including laminin-332, nidogen, and type IV collagen. In UVB-damaged human skin tissue, Exo-Cica/HA restored collagen and elastic fibers and improved dermal–epidermal junction morphology. Furthermore, it accelerated keratinocyte migration and re-epithelialization in both in vitro and ex vivo wound models. Conclusion: Exo-Cica/HA enhances coordinated skin rejuvenation by modulating inflammation, reinforcing epidermal barrier function, improving basement membrane integrity, and reconstructing the ECM, supporting its potential as a biologically active wound-covering material. Keywords: Exosome; Hyaluronic acid; Rejuvenation; Extracellular matrix; Scar

• BLOG 2026.08.06

  Plant-based Exosomes for Skin Repair: Modulating Inflammatory Cell Count in an Experimental Wound Model

  Purpose: This study investigated the effect of locally injected plant-derived exosomes on inflammatory cell dynamics during skin wound healing in a rat model. Materials and Methods: Twenty-four adult Wistar albino rats were randomly assigned into two groups (n =12 each). A standardized 1-cm full-thickness incision was created on the ventral surface of the forelimbs in all animals. Group 1 served as the control with no additional treatment, while Group 2 received intradermal injections of plant-derived exosomes (Exoline Exosomes®, Abiomaterials Co., Ltd., South Korea) directly into the wound bed immediately after incision. Biopsy samples were collected under anesthesia at baseline, day 7, and day 14 post-wounding. Histological analysis using Hematoxylin and Eosin staining quantified inflammatory cell infiltration. Histological evaluation was conducted by a blinded pathologist to minimize observer bias. Results: The group treated with plant-derived exosomes exhibited a marked reduction in inflammatory cell infiltration at all observed time points compared to the control group. Histological analysis revealed that wounds in the exosome-treated animals demonstrated more organized tissue architecture and a faster resolution of the inflammatory phase. These findings suggest that exosome administration effectively modulates the local immune response, promoting accelerated wound healing. Conclusion: Intradermal injection of plant-derived exosomes significantly modulates the inflammatory phase of skin wound healing, reducing inflammatory cell infiltration and enhancing tissue regeneration. These findings support the potential of plant based exosomes as a novel, safe, and effective therapy for promoting cutaneous wound repair. Keywords: Introduction animal studies, exosomes, experimental study, plant based exosomes, scars, skin wounds, wound healing

• BLOG 2026.08.06

  Experience in Treatment of Patchy Alopecia Areata with Advanced Adipose-Derived Stem Cells Protein Extract (AAPE)

  Background and Objectives: Alopecia areata is a common disease, which causes significant cosmetic and psycho-social distress for most of the people it affects. The most evidence-based hypothesis is an autoimmune reaction caused by the loss of hair follicle immune privilege. Immune privilege loss is assumed to be either a primary event that triggers antigen presentation in a disturbed hair follicle environment or an event that occurs as a result of central immune system dysregulation that involves the follicles. Several gene loci have been identified with alopecia areata. In this study, we report an innovative form of treatment with AAPE in a patient with advanced chronic alopecia areata.   Study Design/Patients and Methods: In this case report, I have investigated the therapeutic effect of a single treatment session using AAPE in a female patient with a challenging form of alopecia areata. Results: Treating the patient with AAPE resulted in no adverse effects after the session, significant satisfactory regrowth of healthy hair in the entire treated area. In the six months follow-up period, there was no evidence of relapse in the treated areas. Conclusions: Intradermal application of AAPE has been proved to be successful, safe treatment and easy to apply. The recovery was very satisfying even after 6 months post AAPE only.

• BLOG 2026.08.06

  Hair Regeneration Therapy Using an Adipose-Derived Stem Cell Conditioned Medium

  BACKGROUND An adipose-derived stem cell–conditioned medium (ADSC-CM) reportedly exerts skin rejuvenating and hair growth-promoting effects. In the therapeutic application of ADSC-CM for alopecia, changes to the interfollicular scalp remain unclear although some evidence has indicated hair growth promoting effects. OBJECTIVE To evaluate the effects of ADSC-CM not only on hair follicles, but also on the interfollicular scalp. METHODS Forty patients (21 men, 19 women; age range, 23–74 years) with alopecia were treated by intra dermal injection of ADSC-CM every month for 6 months. Eighty fixed sites on patients were investigated by trichograms, physiological examinations, and ultrasonographic examinations at 4 time points (before treat ment and 2, 4, and 6 months after the initial treatment). RESULTS Hair density and anagen hair rate increased significantly. As physiological parameters, trans epidermal water loss value gradually increased, with significant differences at 4 and 6 months after the initial treatment, but hydration state of the stratum corneum and skin surface lipid level showed no obvious changes. As ultrasonographic parameters, dermal thickness and dermal echogenicity were increased significantly. CONCLUSION Intradermal administration of ADSC-CM on the scalp has strong potential to provide regen erative effects for hair follicles and the interfollicular scalp. An adipose-derived stem cell–conditioned medium offers a promising prospect as an alternative treatment for alopecia. The authors have indicated no significant interest with commercial supporters

• BLOG 2026.08.06

  Exosomes from human adipose derived stem cells promote proliferation and migration of skin fibroblasts

  This study was undertaken to evaluate whether exosomes from human adipose derived stem cells (ASC-exo) can stimulate the regeneration of human dermal fibroblasts (HDFs). Immunoblotting and FACS analyses showed that ASC-Exo was positive for exosome markers. Fluorescence tracking revealed that the contents of ASC-exo was transferred into the HDFs. ASC-exo treatment also stimulated the proliferation and migration of HDFs in a dose dependent manner. Similarly, the expression levels of genes involved in skin cell proliferation were increased by ASC-exo. Microarray analysis showed an enrichment of microRNAs that have regenerative function. We suggest that the ASC-exo can stimulate skin cell proliferation. 

• BLOG 2026.08.06

  Hair Regeneration Therapy: Application of Adipose-Derived Stem Cells

  Abstract: Background: Adipose-derived stem cells secrete various cytokines that promote hair growth. Objective: To describe our experience of hair regeneration therapy using adipose-derived stem cell conditioned medium. Results: We performed the hair regeneration therapy in numerous Japanese patients and reported good results. We described characteristics of the commercialized conditioned medium, treatment methods, and future directions. Conclusion: Treatment using adipose-derived stem cell-conditioned medium is highly effective and may represent a new therapy for alopecia.

VIEW MORE